 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2020, vol. 26, issue2
Subject Area: Dental Medicine
-
DOI: 10.5272/jimab.2020262.3144
Published online: 20 May 2020
Review article
J of IMAB. 2020 Apr-Jun;26(2):3144-3154
DENTAL CONSIDERATIONS IN PATIENTS TAKING NEW ANTIPLATELET AND ANTICOAGULANT DRUGS
Atanaska S. Dinkova1
, Hristo I. Daskalov1, Delian Delev2,
1) Department of Oral Surgery, Faculty of Dental Medicine, Medical University of Plovdiv, Bulgaria.
2) Department of Pharmacology and Clinical Pharmacology, Medical University of Plovdiv, Bulgaria.
ABSTRACT:
Atherosclerosis and the resulting cardiovascular and cerebrovascular diseases (myocardial infarction, coronary artery disease and stroke) are the leading cause of mortality and morbidity in the developed countries. Worldwide, over 10 million deaths per annum are caused by arterial thrombosis (ischaemic stroke, heart disease, peripheral gangrene).
Leading in the treatment and prevention of thrombotic complications are the anticoagulant and antiplatelet drugs which are taken by millions of patients worldwide.
A review of the literature shows that clinical trials involving dental extractions in patients taking antithrombotic drugs have been conducted for more than 50 years and are still ongoing.
Recently, new antiplatelet and anticoagulant drugs: direct thrombin inhibitors, factor Xa inhibitors and a new class of oral thienopyridines (inhibitors of Glycoprotein IIb/IIIa and P2Y12 receptors) have been introduced on the market and are becoming increasingly common. The implications of these drugs during dental treatment are not yet known, and there is not enough information available within the literature on safe use during dental surgery. The purpose of the present review is to discuss the pharmacological properties of the new antiplatelet and anticoagulant drugs, their usage in the perioperative setting, and some guidance for dental practitioners performing invasive dental procedures.
Keywords: haemostasis alteration, blood coagulation disorders, new antiplatelet drugs, dental management antiplatelet, oral surgery, NOA, thrombosis,
- Download FULL TEXT /PDF 574 KB/
Please cite this article as: Dinkova AS, Daskalov HI, Delev D. Dental considerations in patients taking new antiplatelet and anticoagulant drugs. J of IMAB. 2020 Apr-Jun;26(2):3144-3154.
DOI: 10.5272/jimab.2020262.3144
Correspondence to: Atanaska Spasova Dinkova DMD, PhD., Oral surgery department, Faculty of dental medicine, Medical University of Plovdiv; 3, Hristo Botev blvd., Plovdiv, Bulgaria; E-mail: dinkova_asia@yahoo.com
REFERENCES:
1. Murray CJ, Lopez AD. Alternative Projections of Mortality and Disability by Cause 1990-2020: Global Burden of Disease Study. Lancet. 1997 May 24;349(9064):1498-504. [PubMed] [Crossref]
2. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015 Aug;12(8):464-474. [PubMed] [Crossref]
3. Kannan M, Ahmad F, Renu Saxena R. Platelet Activation Markers in Evaluation of Thrombotic Risk Factors in Various Clinical Settings. Blood Rev. 2019 Sep;37:100583. [PubMed] [Crossref]
4. Mega JL, T. Simon. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet, 386 (9990) (2015), pp. 281-291 [PubMed] [Crossref]
5. Sarich TC, Seltzer JH, Berkowitz CD, Costin J, Curnutte JT, Michael Gibson C, et al. Novel Oral Anticoagulants and Reversal Agents: Considerations for Clinical Development. Am Heart J. 2015 Jun;169(6):751-7. [PubMed] [Crossref]
6. Jakubowski JA, Matsushima N, Asai F, Naganuma H, Brandt JT, Hirota T et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J ClinPharmacol 2007; 63: 421–430. [PubMed] [Crossref]
7. Umemura K, Iwaki T. The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers.ClinPharmacol Drug Dev. 2016;5(6):480–487. [PubMed] [Crossref]
8. Martin AC, Zlotnik D, Porta Bonete G, Baron E, Decouture B, Belleville-Rolland T, et al. Epinephrine Restores Platelet Functions Inhibited by Ticagrelor: A Mechanistic Approach. Eur J Pharmacol. 2020 Jan 5;866:172798. [PubMed] [Crossref]
9. Koenig-Oberhuber V, Filipovic M. New antiplatelet drugs and new oral anticoagulants. Br J Anaesth. 2016; 117 (S2): ii74-ii84 [PubMed] [Crossref]
10. Baker DE, Ingram KT. Cangrelor. Hosp Pharm. 2015 Nov;50(10):922-9 [PubMed] [Crossref]
11. Coller BS. Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy. Circulation. 1995 Nov;92(9):2373-80 [PubMed] [Crossref]
12. Cox D. Oral GPIIb/IIIa Antagonists: What Went Wrong? Curr Pharm Des. 2004; 10(14):1587-96. [PubMed] [Crossref]
13. Gross L, Aradi D, Sibbing D. Platelet Function Testing in Patients on Antiplatelet Medications. Semin Thromb Hemost. 2016 Apr;42(3):306-20 [PubMed] [Crossref]
14. Sambu N, Curzen N. Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations. Br J Clin Pharmacol. 2011 Oct; 72(4): 683–696 [PubMed] [Crossref]
15. Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs. Dental Clinical Guidance. Scottish Dental Clinical Effectiveness Programme (SDCEP). August 2015. [Internet]
16. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012 Jul;126(3):343-8 [PubMed] [Crossref]
17. Bajkin BV, Vujkov SB, Milekic BR, Biljana A. Vuckovic BA. Risk factors for bleeding after oral surgery in patients who continued using oral anticoagulant therapy. J Am Dent Assoc. 2015; 146 (6): 375-381 [PubMed] [Crossref]
18. Thean D, Alberghini M. Anticoagulant therapy and its impact on dental patients: a review. Aust Dent J. 2016 Jun;61(2):149-56 [PubMed] [Crossref]
19. Patton LL, Glick M, editors. The ADA Practical Guide to Patients with Medical Conditions. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2016. p. 25-42.
20. Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Apr;113(4):431-41 [PubMed] [Crossref]
21. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral Anticoagulant Therapy. Antithrombotic Therapy and Prevention of Thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e44S-e88S [PubMed] [Crossref]
22. Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015 Jun;11:967-77. [PubMed] [Crossref]
23. Baker WL, Johnson SG. Pharmacogenetics and oral antithrombotic drugs. Curr Opin Pharmacol. 2016 Apr;27:38-42 [PubMed] [Crossref]
24. O'Connell JE, Stassen LFA. New Oral Anticoagulants and Their Implications for Dental Patients. J Ir Dent Assoc. 2014 Jun-Jul;60(3):137-43. [PubMed]
25. Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol. 2010;(196):407‐418. [PubMed] [Crossref]
26. Muñoz-Corcuera M, Ramírez-Martínez-Acitores L, López-Pintor R-M, Casañas-Gil E, Hernández-Vallejo G. Dabigatran: A new oral anticoagulant. Guidelines to follow in oral surgery procedures. A systematic review of the literature. Med Oral Patol Oral Cir Bucal. 2016 Nov 1;21(6):e679-e688. [PubMed] [Crossref]
27. Byon W, Sweeney K, Frost C, Boyd RA. Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism. CPT PharmacometricsSystPharmacol. 2017; 6(5):340–349. [PubMed] [Crossref]
28. Gulilat M, Tang A, Gryn SE, Leong-Sit P, Skanes AC, Alfonsi JE, et al. Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care. Can J Cardiol. 2017;33(8):1036‐1043. [PubMed] [Crossref]
29. De Caterina R, Ageno W, Boriani G, Colonna P, Ghirarduzzi A, Patti G et al. Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. AdvTher. 2017;34(3):620–637. [PubMed] [Crossref]
30. Husted S, Verheugt FWA, Comuth WJ. Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives. Drug Saf. 2016 Jan;39(1):5-13. [PubMed] [Crossref]
31. Morimoto Y, Yokoe C, Imai Y, Sugihara M, Futatsuki T. Tooth Extraction in Patients Taking Nonvitamin K Antagonist Oral Anticoagulants. J Dent Sci. 2016 Mar;11(1):59-64. [PubMed] [Crossref]
32. Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015 Aug 6;373(6):511-20. [PubMed] [Crossref]
33. Di Minno A, Frigerio B, Spadarella G, Ravani A, Sansaro D, Amato M, et al. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev. 2017 Jul;31(4):193-203 [PubMed] [Crossref]
34. StöllbergerC. Drug interactions with new oral anticoagulants in elderly patients. Expert Rev Clin Pharmacol<. 2017 Nov;10(11):1191-1202 [PubMed] [Crossref]
35. Elad S, Marshall J, Meyerowitz C, Connolly G. Novel Anticoagulants: General Overview and Practical Considerations for Dental Practitioners. Oral Dis. 2016 Jan;22(1):23-32. [PubMed] [Crossref]
36. Johnston S. An Evidence Summary of the Management of Patients Taking Direct Oral Anticoagulants (DOACs) Undergoing Dental Surgery. Int J Oral Maxillofac Surg. 2016 May;45(5):618-30. [PubMed] [Crossref]
37. Curto A, Albaladejo A, Alvarado A. Dental Management of Patients Taking Novel Oral Anticoagulants (NOAs): Dabigatran. J ClinExp Dent. 2017 Feb 1;9(2):e289-e293. [PubMed] [Crossref].
Received: 08 July 2019
Published online: 20 May 2020